Neuromuscular Disorders

Papers
(The H4-Index of Neuromuscular Disorders is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
WMS General Information64
ENMC Themed Workshop announcement50
WMS General Information43
Editorial Board39
ENMC Mid-Career Mentoring Programme37
366P Social Vulnerability in Duchenne Muscular Dystrophy: The Impact on Boys and Carrier Mothers35
156P Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma in clinically silent and childhood-onset SMA individuals from Serbia34
355P A comprehensive education and training programme for healthcare professionals in care and research for Duchenne muscular dystrophy developed from DMD Care UK and the DMD Hub32
624P A new double-trouble phenotype: fascioscapulohumeral muscular dystrophy and familial amyotrophic lateral sclerosis.31
81P Minimal clinically important differences in dysferlinopathy from the 10-year, multicenter Jain Clinical Outcome Study28
326P Acute adverse events after Zoledronic acid infusion are uncommon in patients with Duchenne muscular dystrophy previously treated with oral bisphosphonates27
279P Exploring myogenic tremor in an animal model of MYBPC1-associated myopathy: a comprehensive study25
95P Development of a myotropic gene therapy towards a first treatment for LGMDR724
365P Duchenne video assessment 2.0 scorecard performance: evaluation of inter-item and inter-scorecard relationships22
WMS 2024 Full Programme22
46P Congenital myopathies and muscular dystrophies in the UK: a comprehensive next generation sequencing analysis of frequencies over an 8-year period (2016-2023)21
203P Towards a better analysis of SMN2 structures and variants by complete sequencing of the SMN locus in an international cohort of 564 SMA patients21
389P Natural history of bone health in Duchenne muscular dystrophy: A systematic review and implications for the design of a clinical trial21
17O Schwann cell transduction and PMP22 target engagement in non-human primates supports translation of RNAi-based gene therapy for CMT1A21
686P Identification and characterization of actionable deep intron 8 IGHMBP2 hotspot pathogenic variants through motor neuron RNAseq and whole genome20
271P Exploring the effects of the epi-drug Remodelin on murine myoblasts differentiation20
10O The neonatal screening of SMA in Ukraine: the 18 months of experience20
0.14282011985779